Ashley E. Ross, MD, PhD

Bobby Liaw, MD, reviews the study design and results of the phase 3 ENZAMET study and discusses an ongoing trial in mCSPC, ARASENS.

Ashley E. Ross, MD, PhD, reviews data and study results from the phase 3 TITAN and phase 3 ARCHES trial in mCSPC.

Vivek K. Narayan, MD, MS, provides insight on the evolution of care for mCSPC and the current use of ARI-directed therapy for disease management.

Experts in prostate cancer comment on the role of urologists in performing molecular testing and share how they facilitate treatment of advanced prostate cancer across multiple disciplines.

Ashley E. Ross, MD, PhD, leads the discussion on risk stratification in advanced prostate cancer and approaching prostate cancer screening.

Bobby Liaw, MD; Neal Shore, MD, FACS; and Vivek K. Narayan, MD, MS, discuss the incidence and prevalence of advanced prostate cancer, including mCSPC and nmCRPC.

"Every effort should be made to reduce the cost of molecular testing and expand their access," writes Ashley Ross, MD, PhD.